Filing Flows › Lenz Therapeutics (LENZ) › Q3 2025
Lenz Therapeutics (LENZ) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Lenz Therapeutics (LENZ) reported revenue of $12.5M for the third quarter 2025 (Q3 2025) and +150% from the quarter before. Operating margin was -151.1%, net loss $16.7M (133.6% of revenue).
Lenz Therapeutics, Q3 2025: revenue $12.5M, operating margin -151.1%, net loss $16.7M, operating cash flow −$8.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.5M | +150% | — |
| Operating profit | −$18.9M | — | — |
| Net earnings | −$16.7M | — | — |
| Operating cash flow | −$8.6M | — | — |
What changed
Revenue was $12.5M in Q3 2025, up 150% from the previous quarter.
Operating costs exceeded revenue by $18.9M, an operating margin of -151.1%. The quarter ended with a net loss of $16.7M, wider than the previous quarter's $14.9M loss.
Operating cash flow was −$8.6M. Non-cash charges added back $125K of depreciation and amortization and $3.5M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $439K exceeded it, leaving free cash flow of −$9.0M.
Questions
What was Lenz Therapeutics' revenue in the third quarter 2025?
Lenz Therapeutics (LENZ) reported revenue of $12.5M for the third quarter 2025 (Q3 2025) and +150% from the quarter before.
Was Lenz Therapeutics profitable in the third quarter 2025?
Operating loss was $18.9M (-151.1% of revenue) and net loss $16.7M.
Source: Lenz Therapeutics 10-Q on SEC EDGAR.